Loading organizations...
Bina Technologies has raised $9.0M across 3 funding rounds.
Key people at Bina Technologies.
Bina Technologies has raised $9.0M in total across 3 funding rounds.
Bina Technologies is a Redwood City, California-based bioinformatics company that develops big data software platforms for processing, managing, and analyzing next-generation sequencing genomic data. The enterprise platform simplifies complex genetic datasets for clinical researchers, life sciences organizations, and academic institutions, reducing the time and cost required to accelerate personalized medicine and oncology research. Prior to its acquisition, the B2B enterprise software provider operated with approximately 50 employees and raised $10.55 million in total venture funding. The company secured financial backing from notable venture capital firms including Sierra Ventures and Jerry Yang's AME Cloud Ventures before being acquired by pharmaceutical giant Roche in December 2014. Following the transaction, the organization's technology and personnel were integrated directly into the Roche Sequencing Solutions division. Bina Technologies was originally founded in 2011 by Narges Bani Asadi and Mark Chaisson.
Key people at Bina Technologies.
Bina Technologies has raised $9.0M across 3 funding rounds. Most recently, it raised $2.0M Series B in July 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2013 | $2M Series B | AME Cloud Ventures, Mohsen Moazami | Hardware Club, Lakestar, Mosaic Ventures | Announced |
| Mar 1, 2013 | $6M Series B | Sierra Ventures | C2 Investment | Announced |
| Apr 1, 2011 | $1M Series A | — | — | Announced |
Bina Technologies has raised $9.0M in total across 3 funding rounds.
Bina Technologies's investors include AME Cloud Ventures, Mohsen Moazami, Hardware Club, Lakestar, Mosaic Ventures, Sierra Ventures, C2Ventures.
Bina Technologies developed a Genomic Management Solution (Bina-GMS), a big data platform for scalable processing and analysis of next-generation sequencing (NGS) genomic data.[1][3][5] It served clinical and translational researchers by simplifying complex genomic datasets, reducing analysis time and costs to accelerate personalized medicine.[1][3] The company raised $10.55M from investors including Roche, AME Cloud Ventures, and Sierra Ventures before being acquired by Roche in 2014, after which it integrated into Roche's Sequencing Unit.[1][3]
Bina Technologies emerged from stealth mode around 2013-2014, headquartered in Redwood City, California, with a mission to redefine personalized, data-driven healthcare through genomic analytics.[3][4][6] Founders and early team details are not specified in available records, but the company quickly gained traction by building proprietary technologies for NGS data management, leading to a commercial launch planned for February (year unspecified in sources).[6] A pivotal moment came in December 2014 when Roche acquired Bina to enter the genomic informatics market, enabling accelerated product development and global expansion.[3]
Bina rode the early 2010s explosion in NGS technologies, where plummeting sequencing costs generated massive data volumes requiring advanced informatics for personalized medicine.[3] Timing was ideal amid rising demand for scalable genomic analysis in oncology, immunology, and beyond, aligning with Roche's diagnostics leadership.[3] Market forces like big data challenges in biotech favored Bina's solutions, influencing the ecosystem by integrating into Roche's portfolio to enhance global genomic research tools and accelerate translation from data to clinical insights.[1][3]
Post-2014 acquisition, Bina's technologies likely advanced within Roche's Sequencing Unit, contributing to expanded genomic analysis portfolios amid ongoing NGS adoption and AI-driven bioinformatics trends. Future shape comes from precision medicine growth, multi-omics integration, and cloud-based scaling, potentially evolving Bina's legacy into broader enterprise tools influencing diagnostics and drug discovery. This positions its foundational work as a key enabler in data-driven healthcare transformation.
